piwik-script

Deutsch Intern
    Institute for Clinical Epidemiology and Biometry

    UNITI

    Unification of treatments and Interventions for Tinnitus patients

    Coordinator UNITI :

    Winfried Schlee, University of Regensburg, Germany

    Coordination of WP 4 (harmonisation of technical solutions):

    Prof. Rüdiger PryssCarsten Vogel

    Founder:

    European Union Research and Innovation programme Horizon 2020

    Status:

    Duration 39 months, start date 01 Jan 2020, grant number 848261

     

    Description

    Tinnitus is the perception of a phantom sound and the patient’s reaction to it. Tinnitus remains a scientific and clinical enigma of iTinnitus is the perception of a phantom sound and the patient’s reaction to it. Although much progress has been made, tinnitus remains a scientific and clinical enigma of high prevalence and high economic burden. It affects more than 10% of the general population, whereas 1% of the population considers tinnitus their major health issue. Recent cohort studies show that tinnitus prevalence tends to increase over time and with older age. Assuming that there is no cure to be found, the prevalence estimates in Europe would double by 2050. A large variety of patient characteristics - including genotyping, aetiology, and phenotyping - are poorly understood, because integrated systems approaches are still missing to correlate patient`s characteristics to predict responses to combinatorial therapies.

    Although genetic causes of tinnitus have been neglected for decades, recent findings of genetic analysis in specific subgroups (gender and phenotype) have highlighted that bilateral tinnitus in men reached a heritability of 0.68. This heritability is close to autism, schizophrenia and Attention Deficit Hyperactive Disorder (ADHD). There is no current consensus on tinnitus treatment. UNITI’s overall aim is to deliver a predictive computational model based on existing and longitudinal data attempting to address the question which treatment approach is optimal for a specific patient based on specific parameters. Clinical, epidemiological, medical, genetic and audiological data, including signals reflecting ear-brain communication, will be analysed from existing databases. Predictive factors for different patient groups will be extracted and their prognostic relevance will be tested in a randomized controlled trial (RCT) in which different groups of patients will undergo a combination of therapies targeting the auditory and central nervous systems.

    Work Packages

    Workpackage Content Responsibility
    WP1 Ethics University of Regensburg (UHREG)
    WP2 Project Management University of Regensburg (REG)
    WP3 Analysis of existing data University of Magdeburg (MAG)
    WP4 Harmonization of technical solutions Julius-Maximilians-Universität Würzburg (JMU)
    WP5 Intelligent data analysis ICCS
    WP6 Genetics GRA
    WP7 Randomized Clinical Trial University of Regensburg (REG)
    WP8 Dissemination, Communication and Exploitation VIL

     

    Overview

    UNITI Workpackages Overview

    Partners

    No Name Short name Country Project entry month Project exit month

    1.

    KLINIKUM DER UNIVERSITAET REGENSBURG UHREG

    Germany

    1 39

    2.

    KATHOLIEKE UNIVERSITEIT LEUVEN KUL

    Belgium

    1 39

    3.

    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON UOA

    Greece

    1 39

    4.

    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

    CHA

    Germany

    1 39

    5.

    SERVICIO ANDALUZ DE SALUD

    GRA

    Spain

    1 39

    6.

    KAROLINSKA INSTITUTET

    KI

    Sweden

    1 39

    7.

    OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG

    MAG

    Germany

    1 39

    8.

    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS- UNIVERSITAET

    JMU

    Germany 1 39

    9.

    INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS

    ICCS

    Greece 1 39

    10.

    ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI MIL Italy 1 39

    11.

    VILABS (CY) LTD VIL Cyprus 1 39

    12.

    SPHYNX TECHNOLOGY SOLUTIONS AG

    SPX

    Switzerland 1 39

    13.

    ZEINCRO EGESZSEGUGYI SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG

    ZEI Hungary 1 39